THE TIME COURSE OF CUTANEOUS PORPHYRIN PHOTOSENSITIZATION IN THE MURINE EAR

Abstract This study was designed to investigate the time course of acute cutaneous photosensitivity following administration of Photofrin II using the murine ear swelling response (ESR) as an in vivo end‐point. Ros:(ICR) mice were injected with 5 mg/kg Photofrin II and illuminated 7.5 h to 31 days later with 630‐nm laser light; ESR was measured 24 h after illumination. There was a direct correlation between ESR and the concentration of [14C]Photofrin II in blood, while no relationship between ESR and the level of [14C]Photofrin II in the ear tissue of exsanguinated mice was evident. Photosensitivity in the mouse foot can be suppressed by preexposure to low doses of light via a photochemical destruction of tissue‐bound sensitizer (Boyle and Potter, 1987, Photochem. Photobiol. 46, 997–1001). However, mouse ears pretreated with 84 J/cm2 of 630‐nm light (28 J/cm2/day, given 2, 4 and 6 d after injection), a dose sufficient to reduce porphyrin fluorescence in ear tissue by about 75%, prior to the usual light dose (88.6 J/cm2, 630 nm, day 9 after injection) showed a mean ESR not significantly different (P > 0.5) from that for ears which received only a single dose of 88.6 J/cm2 on day 9. It is concluded, for this animal model, that circulating porphyrin is the source of photoinduced ear‐tissue edema and that photobleaching of tissue‐bound sensitizer does not attenuate ear‐tissue photosensitivity.

[1]  T. Dougherty,et al.  Determination of [3H]- and [14C]hematoporphyrin derivative distribution in malignant and normal tissue. , 1979, Cancer research.

[2]  T. J. Williams,et al.  PROSTAGLANDIN E2, PROSTAGLANDIN I2 AND THE VASCULAR CHANGES OF INFLAMMATION , 1979, British journal of pharmacology.

[3]  I. Gigli,et al.  PHOTOTOXICITY INDUCED BY HEMATOPORPHYRIN DERIVATIVE IN C5‐DEFICIENT, MAST CELL‐DEFICIENT AND LEUKOPENIC MICE , 1986, Photochemistry and photobiology.

[4]  C. Elmets,et al.  Cutaneous porphyrin photosensitization: murine ear swelling as a marker of the acute response. , 1986, The Journal of investigative dermatology.

[5]  T. Mang,et al.  Photofrin II levels by in vivo fluorescence photometry. , 1984, Progress in clinical and biological research.

[6]  C. Elmets,et al.  Immunological suppression in mice treated with hematoporphyrin derivative photoradiation. , 1986, Cancer research.

[7]  F. Kerdel,et al.  In vivo mediator release and degranulation of mast cells in hematoporphyrin derivative-induced phototoxicity in mice. , 1987, The Journal of investigative dermatology.

[8]  A E Profio,et al.  SKIN PHOTOSENSITIVITY: DURATION and INTENSITY FOLLOWING INTRAVENOUS HEMATOPORPHYRIN DERIVATES, HpD and DHE , 1987, Photochemistry and photobiology.

[9]  J Moan,et al.  PHOTOBLEACHING OF PORPHYRINS USED IN PHOTODYNAMIC THERAPY AND IMPLICATIONS FOR THERAPY , 1987, Photochemistry and photobiology.

[10]  W. Potter,et al.  PHOTOBLEACHING OF PHOTOFRIN II AS A MEANS OF ELIMINATING SKIN PHOTOSENSITIVITY * , 1987, Photochemistry and photobiology.

[11]  Kevin C. Smith,et al.  Prospective study of cutaneous phototoxicity after systemic hematoporphyrin derivative , 1988, Lasers in surgery and medicine.

[12]  T. Dougherty,et al.  CARBON‐14 LABELING AND BIOLOGICAL ACTIVITY OF THE TUMOR‐LOCALIZING DERIVATIVE OF HEMATOPORPHYRIN , 1988, Photochemistry and photobiology.

[13]  T. Williams,et al.  Control of vascular permeability by polymorphonuclear leukocytes in inflammation , 1981, Nature.

[14]  W. Potter,et al.  DRUG AND LIGHT DOSE DEPENDENCE OF PHOTODYNAMIC THERAPY: A STUDY OF TUMOR CELL CLONOGENICITY AND HISTOLOGIC CHANGES , 1987, Photochemistry and photobiology.

[15]  G. Jori,et al.  Role of high-, low- and very low-density lipoproteins in the transport and tumor-delivery of hematoporphyrin in vivo. , 1986, Cancer letters.